CN111110600B - 一种头皮净化促生发组合物及其乳液 - Google Patents
一种头皮净化促生发组合物及其乳液 Download PDFInfo
- Publication number
- CN111110600B CN111110600B CN201911413315.8A CN201911413315A CN111110600B CN 111110600 B CN111110600 B CN 111110600B CN 201911413315 A CN201911413315 A CN 201911413315A CN 111110600 B CN111110600 B CN 111110600B
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- scalp
- hair growth
- promoting composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 210000004761 scalp Anatomy 0.000 title claims abstract description 55
- 239000000839 emulsion Substances 0.000 title claims abstract description 41
- 230000001737 promoting effect Effects 0.000 title claims abstract description 41
- 230000003779 hair growth Effects 0.000 title claims abstract description 34
- 238000000746 purification Methods 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 35
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 30
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims abstract description 20
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims abstract description 10
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940100554 isononyl isononanoate Drugs 0.000 claims abstract description 10
- SAVLIIGUQOSOEP-UHFFFAOYSA-N N-octanoylglycine Chemical compound CCCCCCCC(=O)NCC(O)=O SAVLIIGUQOSOEP-UHFFFAOYSA-N 0.000 claims abstract description 9
- -1 dimethyl isosorbide anhydride Chemical class 0.000 claims abstract description 9
- 239000000294 eucalyptus globulus labille leaf/twig oil Substances 0.000 claims abstract description 9
- 239000001198 melaleuca alternifolia leaf oil Substances 0.000 claims abstract description 9
- 229910000278 bentonite Inorganic materials 0.000 claims abstract description 8
- 239000000440 bentonite Substances 0.000 claims abstract description 8
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 5
- 235000016709 nutrition Nutrition 0.000 claims abstract description 5
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 claims abstract description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 230000035515 penetration Effects 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 9
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 9
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 9
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 229960005305 adenosine Drugs 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 239000011616 biotin Substances 0.000 claims description 9
- 229960002685 biotin Drugs 0.000 claims description 9
- 235000020958 biotin Nutrition 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 229910052802 copper Inorganic materials 0.000 claims description 9
- 239000010949 copper Substances 0.000 claims description 9
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 9
- 229960000367 inositol Drugs 0.000 claims description 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 241000208843 Arctium Species 0.000 claims description 7
- 235000003130 Arctium lappa Nutrition 0.000 claims description 7
- 235000008078 Arctium minus Nutrition 0.000 claims description 7
- 229940092782 bentonite Drugs 0.000 claims description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 229940107131 ginseng root Drugs 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- RRJOMESUBQAYOA-BZSNNMDCSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-aminohexanamide Chemical compound NCCCC[C@H](NC(=O)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 RRJOMESUBQAYOA-BZSNNMDCSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 5
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 claims description 5
- 229960000541 cetyl alcohol Drugs 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229960003966 nicotinamide Drugs 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 5
- 229940113124 polysorbate 60 Drugs 0.000 claims description 5
- 229940083982 sodium phytate Drugs 0.000 claims description 5
- 229950011392 sorbitan stearate Drugs 0.000 claims description 5
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
- 239000001967 plate count agar Substances 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 241000208340 Araliaceae Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 229940074928 isopropyl myristate Drugs 0.000 claims description 3
- 229940033355 lauric acid Drugs 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 claims description 2
- 241001521402 Maackia <angiosperm> Species 0.000 claims description 2
- 241000612118 Samolus valerandi Species 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 241000246044 Sophora flavescens Species 0.000 claims 1
- 230000003385 bacteriostatic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004209 hair Anatomy 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000003658 preventing hair loss Effects 0.000 abstract description 4
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 15
- 231100000360 alopecia Toxicity 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 210000002374 sebum Anatomy 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 230000003656 anti-hair-loss Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 230000036619 pore blockages Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000000283 familial pityriasis rubra pilaris Diseases 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 230000003662 hair growth rate Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/008—Preparations for oily hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆品技术领域，具体涉及一种头皮净化促生发组合物及其乳液。本发明提供一种头皮净化促生发组合物及其乳液，所述组合物包括头皮净化组合物、促渗组合物、促生发组合物和头皮营养组合物，所述头皮净化组合物由包括辛酰甘氨酸、PCA锌、膨润土、烟酰胺、苦参提取物、互生叶白千层叶油和蓝桉叶油，所述促渗组合物包括丙二醇、异山梨醇酐二甲醚、异壬酸异壬酯、肉豆蔻酸异丙酯和十二酸。本发明所述头皮净化促生发组合物具有控油、防脱、固发的作用，且所述乳液具有稳定性好、经皮吸收性好、制备过程简单的优点，适合工业大量生产。
Description
技术领域
本发明属于化妆品领域，具体涉及一种头皮净化促生发组合物及其乳液。
背景技术
当前，我国脱发人数约2亿，其中有1.3亿为男性，大概每4个中国成年男子中就有1个人在脱发，并且脱发年龄证趋向年轻化。国内外在医学上治疗脱发的分类方法主要有西医治疗和中医治疗，或者分为药物治疗和手术治疗。西医上的治疗方法有外用2％或者5％米诺地尔，或者是口服非那雄胺及其类似药，注射皮质类固醇等，手术治疗有头发移植、低能量激光治疗(LLLT疗法)、自体富血小板血浆(PRP疗法)等，以上方法都会有副作用，也不是适用于所有人群，疗程至少6个月以上。如米诺地尔，不仅可以用于治疗高血压，还可以局部应用于头皮，延长头发的生长周期，但对于由于自身免疫性疾病导致脱发的女性来说，米诺地尔可能仅维持现有的头发而对再生没有任何裨益。
近50年中医把补虚作为治疗基础，在此基础上再依据症型清泄内热、祛浊利湿、活血化瘀等辨证论治。以外治方活血化瘀、辛散透邪、清热化湿为辅助。同时重视调养肝肾和脾胃，并兼顾雄激素性脱发患者的心理治疗。中医治脱的机理相对没那么明确，见效不明显，但也由此催生了高频使用的中药成分，如当归、何首乌、侧栢叶、熟地黄、红花等。
现有的防脱促生发组合物多以传统植物提取物为主，或者加以复配多肽类成分，并且制成水剂使用，其功效发挥的前提是需要经皮吸收至毛囊靶点处。专利文献CN110013455A公开了一种具有止痒、控油、健发、防脱发作用的组合物，虽克服了单纯传统植物提取物治脱发的见效慢的缺点，加入了多肽类成分，但防脱路径并不全面，其所搭配的组合物并没有经皮吸收体系方面的深入研究，对于活性成分能否深入到达靶点位置发挥作用是一个问题。专利文献CN108324610B公开了一种生发组合物并制成PIC纳米乳液，使其具有透皮渗透好、生发效果优异的优点，但没有解决油脂分泌旺盛导致毛孔堵塞的问题，控油效果不突出。专利文献CN108430452A公开了一种包含人参提取物的、防止掉发或促进生发的气溶胶型组合物，使得液态制剂气雾化渗透发挥功效，但功效成分作用途径不全面，也没有毛孔堵塞的问题，制成的组合物没有经皮吸收体系方面的深入研究，对于活性成分能否深入到达靶点位置发挥作用是一个问题。
因此，在育发化妆品效能范围内，减轻脱发的同时，如何有效解决油脂分泌旺盛导致毛孔堵塞的问题和如何将有效成分输送至对应靶点发挥作用，是化妆品行业亟待解决的问题。
发明内容
针对现有技术的不足，本发明提供一种头皮净化促生发组合物及其乳液。本发明所述组合物具有控油、防脱、固发的作用，且所述乳液具有稳定性好、经皮吸收性好、制备过程简单的优点，适合工业大量生产。
为了达到上述目的，本发明采用以下技术方案：
一种头皮净化促生发组合物，其特征在于，所述组合物包括头皮净化组合物、促生发组合物、头皮营养组合物和促渗组合物；所述头皮净化组合物包括辛酰甘氨酸、PCA锌、膨润土、烟酰胺、苦参提取物、互生叶白千层叶油和蓝桉叶油；所述促渗组合物包括丙二醇、异山梨醇酐二甲醚、异壬酸异壬酯、肉豆蔻酸异丙酯和十二酸；所述促生发组合物包括腺苷、乙酰基四肽-3、三肽-1铜、侧柏叶提取物、人参根提取物和五月牛蒡提取物；所述头皮营养组合物包括肌醇、生物素和精氨酸。
优选的，包括如下重量份的组分：头皮净化组合物1～6份、促渗组合物10～30份、腺苷 1～2份、乙酰基四肽-3 0.01～1份、三肽-1铜0.01～1份、侧柏叶提取物1～3份、人参根提取物 1～3份和五月牛蒡提取物1～3份、肌醇1～5份、生物素1～5份、精氨酸0.1～0.5份。
优选的，包括如下重量份的组分：头皮净化组合物5.8份、促渗组合物26.1份、腺苷2 份、乙酰基四肽-3 0.05份、三肽-1铜0.05份、侧柏叶提取物2份、人参根提取物2份和五月牛蒡提取物2份、肌醇2份、生物素1份、精氨酸0.1份。
优选的，所述头皮净化组合物中辛酰甘氨酸、PCA锌、烟酰胺、苦参提取物、互生叶白千层叶油、蓝桉叶油的质量比为(1～2)：(0.5～1)：(1～2)：(1～3)：(0.05～0.1)：(0.05～0.1)。
优选的，所述促渗组合物中丙二醇、异山梨醇酐二甲醚、异壬酸异壬酯、肉豆蔻酸异丙酯、十二酸的质量比为(2～5)：(5～10)：(4～8)：(4～8)：(1～4)。
本发明提供了上述头皮净化促生发组合物在制备乳液中的应用
本发明还提供了一种含有头皮净化促生发组合物的乳液，包括上述头皮净化促生发组合物。
优选的，还包括抑菌组合物、乳化稳定组合物、甘油、植酸钠和十六醇。
优选的，所述抑菌组合物由1,2-戊二醇、乙基己基甘油按照质量比2～5：0.5～3混合而成，所述乳化稳定组合物由山梨坦硬脂酸酯、聚山梨醇酯-60按照质量比0.5～5：0.5～5混合而成。
本发明还提供了一种含有头皮净化促生发组合物的乳液，所述乳液的制备方法包括以下步骤：
(1)根据配方称取各原料，分组备用；
(2)将水、甘油、丙二醇、异山梨醇酐二甲醚、植酸钠、肌醇、烟酰胺、膨润土依次投递加入均质乳化锅的水相锅内，以20r/min的转速搅拌溶解，并加热至80-85℃得到A相；将异壬酸异壬酯、肉豆蔻酸异丙酯、十六醇、十二酸、山梨坦硬脂酸酯、聚山梨醇酯-60、辛酰甘氨酸放入均质乳化锅的油相锅内，以20r/min的转速搅拌溶解，并加热至80～85℃得到B相；
(3)将PCA锌、苦参提取物、腺苷、乙酰基四肽-3、三肽-1铜、侧柏叶提取物、人参根提取物、五月牛蒡提取物、生物素、精氨酸加水溶解得到C相；将互生叶白千层叶油、蓝桉叶油、1,2～戊二醇、乙基己基甘油混合得到D相；
(4)将步骤(2)中得到的A相和B相混合，在70～80℃下以3500r/min均质5～10min，然后在温度为80～85℃的条件下保温15～20min后以10r/min的转速搅拌降温至50℃，然后加入由步骤(3)得到的C相，以3500r/min均质0.5～1min得到混合液E；
(5)将步骤(4)中的混合液E继续搅拌降温至45℃以下，加入D相降温至30℃得到含有头皮净化促生发组合物的乳液。
皮脂的分泌主要受雄性激素、睾酮、脱氢异雄酮的控制，油性头皮在生理方面表现的特征主要是毛孔扩张、角化过度、皮肤微生物增多、皮脂腺分泌过多、毛囊炎症、皮脂腺扩大等，本发明以科学配比采用辛酰甘氨酸、PCA锌、烟酰胺、苦参提取物、互生叶白千层叶油和蓝桉叶油组合，能有效抑制油脂分泌，收敛毛孔，达到控油效果，恢复头皮健康；采用丙二醇、异山梨醇酐二甲醚、异壬酸异壬酯、肉豆蔻酸异丙酯和十二酸等成分促进经皮吸收，辛酰基甘氨酸可抑制毛囊产生的细菌增殖，减少因细菌增殖导致的炎症因子，避免皮脂腺因炎症刺激导致过度分泌；烟酰胺能够促进毛囊血液微循环，调节油脂分泌，实现水油平衡；苦参提取物能够平衡油脂分泌，疏通并收敛毛孔。
与现有技术相比，本发明具有以下优点：本发明中通过促渗组合物能有效将促生发组合物经皮渗透输送至毛囊对应靶点发挥作用，同时本发明中头皮净化组合物能有效控油效果，从而净化头皮，以防止油脂分泌旺盛导致毛孔堵塞而进一步加速头发脱落，并通过兼容性良好的各组分的协同配使得产品达到控油、促渗透、防脱和固发的作用。
附图说明
图1为累计透过量结果。
具体实施方式
以下通过实施例形式的具体实施方式，对本发明的上述内容作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下实施例。
实施例1防脱乳液
制备方法：
(1)根据配方称取各原料，分组备用；
(2)将水、甘油、丙二醇、异山梨醇酐二甲醚、植酸钠、肌醇、烟酰胺、膨润土依次投递加入均质乳化锅的水相锅内，以20r/min的转速搅拌溶解，并加热至80-85℃得到A相；将异壬酸异壬酯、肉豆蔻酸异丙酯、十六醇、十二酸、山梨坦硬脂酸酯、聚山梨醇酯-60、辛酰甘氨酸放入均质乳化锅的油相锅内，以20r/min的转速搅拌溶解，并加热至80-85℃得到B相；
(3)将PCA锌、苦参提取物、腺苷、乙酰基四肽-3、三肽-1铜、侧柏叶提取物、人参根提取物、五月牛蒡提取物、生物素、精氨酸加水溶解得到C相；将互生叶白千层叶油、蓝桉叶油、1,2-戊二醇、乙基己基甘油混合得到D相；
(4)将步骤(2)中得到的A相和B相混合，在70-80℃下以3500r/min均质5-10min，然后在温度为80-85℃的条件下保温15-20min后以10r/min的转速搅拌降温至50℃，然后加入由步骤(3)得到的C相，以3500r/min均质0.5-1min得到混合液E；
(5)将步骤(4)中的混合液E继续搅拌降温至45℃以下，加入D相降温至30℃得到防脱乳液。
实施例2防脱乳液
制备方法同实施例1。
对比例1防脱乳液
对比例1与实施例1的区别在于：无促渗组合物，缺少部分由白油替换，制备方法同实施例1。
对比例2防脱乳液
对比例2与实施例1的区别在于：无头皮净化组合物，缺少部分由膨润土替换，制备方法同实施例1。
对比例3防脱乳液
对比例3与实施例1的区别在于：无头皮净化组合物和无促渗透组合物，缺少头皮净化组合物部分由膨润土替换，缺少促渗组合物部分由白油替换制备方法同实施例1。
试验例1稳定性
将实施例1～2和对比例1～3制得防脱乳液装瓶并放置于分别倒入直径20nm×20nm的试管内，使液面高度约80mm，封口膜封口，把待测试管分别置于预先调节值45℃的恒温箱内和-20℃的冰箱内，分别进行稳定性考察1个星期、3个月和6个月，后取出恢复至室温后与另一试管的试样进行目测比较。
表1稳定性检查结果
从表1结果显示，实施例1～2制备的乳液在稳定性考察1个星期、3个月和6个月后，防脱乳液的pH、浓稠度和气味无明显变化，显示出优良的稳定性，而对比例2和对比例3的pH值变化较为明显，提示头皮净化组合物对防脱乳液的稳定性造成影响，有可能是头皮净化组合物中含有抗微生物成分抑制了微生物生长。
试验例2头皮控油功效评价
测试样品:实施例1和对比例1～3制备的防脱乳液
测试人群：筛选25-45岁头油易痒，有脱发烦恼的志愿者女性10位，志愿者男性20位
测试原理：皮脂测试基于石英水晶传感器技术，通过传感器从头皮上采集皮脂质量。皮脂质量越大，则皮脂含量越多。数值越小，表示皮脂含量越低，产品的控油效果越好。
测试方法：每天早晚各使用1次，1g/次。测试期间，受试者避免过度的紫外线暴露，避免过重体力活动，且测试期间不使用测试样品以外的头部控油产品等，持续使用28天，并在使用后的第0、7、14、28天分别采集受试者头顶位置的皮脂，分别测试头顶位置皮脂，在湿度为40％-60％，温度为20～22℃测试环境进行实时动态监测，结果如表2。
表2头皮油脂含量随时间变化表
表2结果说明，连续使用防脱乳液后，受试部位的油脂含量逐渐较少，但减少程度不同。实施例1组在第14和第28天回访测试时，油脂含量分别下降了23.7％和50.4％，控油效果显著，表明防脱乳液中同时添加了促渗组合物和头皮净化组合物的控油效果明显优于只含单一促生发组合物的防脱乳液。
试验例3经皮吸收渗透效果评价
受试样品：实施例1～2、对比例1～3的防脱乳液
测试方法：
取质量(20±2)g的昆明种小鼠，脱去其腹部被毛，剪下腹部皮肤，除去粘连的脂肪组织，以生理盐水为储存液置于4℃的冰箱中保存备用，临用时吸干皮肤表面水分。将处理好的鼠皮角质层向上固定于Franz扩散池上，接收池中加入30％的乙醇-生理盐水溶液7.5mL，使鼠皮内层完全与接受液接触，打开透皮仪并设定恒温37℃，保持恒定转速200r/min。平衡1h，排尽接收池内的气泡后给药。扩散池供给鼠皮面积上均匀涂上0.1g样品防脱乳液每组平行3次，分别在1.0、2.0、4.0、6.0、8.0、10.0、12.0h时吸取接收液1mL，每次取样后均补入相同体积的接收液，再进行色谱进样分析，测定含促生发组合物的含量，再根据下列公式计算累积透过量(Qn，μg/cm2)。
Qn＝(CnV+ΣCiVi)/A
Cn：第n个时间点吸取液的浓度mg/L
Ci：第n-i个时间点吸取液的浓度mg/L
V：接收液的总体积即
Vi：每次吸取的液体体积
A：接收池的体积
由图1可看出，实施例1～2的累积透过量大于对比例1～2的累积透过量，其中实施例1累计透过量最佳，结果表明防脱乳液中的促渗组合物和头皮净化组合物能够协同促进防脱乳液的透皮吸收，有利于防脱功效的发挥。
试验例4、防脱功效评价
试验样品：实施例1～2和对比例1～3制备的乳液
将有脱发掉发困扰的年龄在20-45岁之间的成年志愿者分成测试组(实施例1～2)和对照组(对比例1～3)，每组共有30名受试者，其中男性15名，女性15名。采用随机、双盲和自身对照的原则，每天早晚使用产品共2次，每次1～2g使用，使用部位是毛发稀疏区。在 16周内的第0周、第8周和第16周，根据受试者的主观判断、洗发时头发脱落筛网收集计数以及通过使，用作为无创毛发评价方法的毛发摄像图来对受试者的毛发密度、毛发生长速率进行评估，结果如表3～5。
表3实施1～2防脱功效对比
表4对比例1～3防脱功效
表5调查问卷反馈结果
防脱功效评价如表3～5，结果显示，经过8周和16周后，实施例1～2的毛发平均密度、毛发平均生长速率显著增加，头发平均掉落根数明显改善，且实施例1中82％的受试者认为掉发量明显减少，85％的人认为头皮油脂分泌有明显改善，而对比例1～3毛发平均密度、毛发平均生长速率和头发平均掉落根数改善效果较差，由此可见，本发明的促渗组合物和头皮净化组合物能够协同促进生发并防止头发脱落。
上述实施例仅例示性说明本发明的原理及其功效，而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下，对上述实施例进行修饰或改变。因此，举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变，仍应由本发明的权利要求所涵盖。
Claims (7)
1.一种头皮净化促生发组合物，其特征在于，所述组合物包括头皮净化组合物、促渗组合物、促生发组合物和头皮营养组合物；
所述头皮净化组合物包括辛酰甘氨酸、PCA锌、膨润土、烟酰胺、苦参提取物、互生叶白千层叶油和蓝桉叶油；
所述促渗组合物包括丙二醇、异山梨醇酐二甲醚、异壬酸异壬酯、肉豆蔻酸异丙酯和十二酸；
所述促生发组合物包括腺苷、乙酰基四肽-3、三肽-1铜、侧柏叶提取物、人参根提取物和五月牛蒡提取物；
所述头皮营养组合物包括肌醇、生物素和精氨酸；
包括如下重量份的组分：头皮净化组合物1～6份、促渗组合物10～30份、腺苷1～2份、乙酰基四肽-3 0.01～1份、三肽-1铜0.01～1份、侧柏叶提取物1～3份、人参根提取物1～3份和五月牛蒡提取物1～3份、肌醇1～5份、生物素1～5份、精氨酸0.1～0.5份；
所述头皮净化组合物中辛酰甘氨酸、PCA锌、烟酰胺、苦参提取物、互生叶白千层叶油、蓝桉叶油的质量比为(1～2)：(0.2～1)：(1～2)：(1～3)：(0.05～0.1)：(0.05～0.1)；所述促渗组合物中丙二醇、异山梨醇酐二甲醚、异壬酸异壬酯、肉豆蔻酸异丙酯、十二酸的质量比为(2～5)：(5～10)：(4～8)：(4～8)：(1～4)。
2.根据权利要求1所述头皮净化促生发组合物，其特征在于，其特征在于，包括如下重量份的组分：头皮净化组合物5.8份、促渗组合物26.1份、腺苷2份、乙酰基四肽-3 0.05份、三肽-1铜0.05份、侧柏叶提取物2份、人参根提取物2份和五月牛蒡提取物2份、肌醇2份、生物素1份、精氨酸0.1份。
3.根据权利要求1所述头皮净化促生发组合物，其特征在于，所述头皮净化组合物中辛酰甘氨酸、PCA锌、烟酰胺、苦参提取物、互生叶白千层叶油和蓝桉叶油的质量比为1：0.2：2：1：0.05：0.05；所述促渗组合物中丙二醇、异山梨醇酐二甲醚、异壬酸异壬酯、肉豆蔻酸异丙酯和十二酸的质量比为3：5：5：5：1。
4.根据权利要求1～3任一项所述的头皮净化促生发组合物在制备乳液中的应用。
5.一种含有头皮净化促生发组合物的乳液，特征在于，包括权利要求1～3任一项所述的头皮净化促生发组合物。
6.根据权利要求5所述含有头皮净化促生发组合物的乳液，其特征在于，还包括抑菌组合物6份、乳化稳定组合物1份、甘油5份、植酸钠0.1份和十六醇2份；
所述抑菌组合物由1,2-戊二醇、乙基己基甘油按照质量比5：1混合而成，所述乳化稳定组合物由山梨坦硬脂酸酯、聚山梨醇酯-60按照质量比1：1混合而成。
7.根据权利要求5所述含有头皮净化促生发组合物的乳液，其特征在于，所述乳液的制备方法包括以下步骤：
(1)根据配方称取各原料，分组备用；
(2)将水、甘油、丙二醇、异山梨醇酐二甲醚、植酸钠、肌醇、烟酰胺、膨润土依次投递加入均质乳化锅的水相锅内，以20r/min的转速搅拌溶解，并加热至80-85℃得到A相；将异壬酸异壬酯、肉豆蔻酸异丙酯、十六醇、十二酸、山梨坦硬脂酸酯、聚山梨醇酯-60、辛酰甘氨酸放入均质乳化锅的油相锅内，以20r/min的转速搅拌溶解，并加热至80～85℃得到B相；
(3)将PCA锌、苦参提取物、腺苷、乙酰基四肽-3、三肽-1铜、侧柏叶提取物、人参根提取物、五月牛蒡提取物、生物素、精氨酸加水溶解得到C相；将互生叶白千层叶油、蓝桉叶油、1,2-戊二醇、乙基己基甘油混合得到D相；
(4)将步骤(2)中得到的A相和B相混合，在70～80℃下以3500r/min均质5～10min，然后在温度为80～85℃的条件下保温15～20min后以10r/min的转速搅拌降温至50℃，然后加入由步骤(3)得到的C相，以3500r/min均质0.5～1min得到混合液E；
(5)将步骤(4)中的混合液E继续搅拌降温至45℃以下，加入D相降温至30℃得到含有头皮净化促生发组合物的乳液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911413315.8A CN111110600B (zh) | 2019-12-31 | 2019-12-31 | 一种头皮净化促生发组合物及其乳液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911413315.8A CN111110600B (zh) | 2019-12-31 | 2019-12-31 | 一种头皮净化促生发组合物及其乳液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111110600A CN111110600A (zh) | 2020-05-08 |
| CN111110600B true CN111110600B (zh) | 2021-08-06 |
Family
ID=70506501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911413315.8A Active CN111110600B (zh) | 2019-12-31 | 2019-12-31 | 一种头皮净化促生发组合物及其乳液 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111110600B (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111658580A (zh) * | 2020-06-23 | 2020-09-15 | 广西和桂集团有限公司 | 含有多种肽与植物提取物的生发和/或白发转黑发精华液及其制备方法 |
| CN112168759A (zh) * | 2020-10-29 | 2021-01-05 | 东方爱堡(北京)母婴健康科技有限公司 | 一种婴幼儿润肤乳及其制备方法 |
| CN112315835A (zh) * | 2020-11-26 | 2021-02-05 | 广州环亚化妆品科技有限公司 | 一种控油去屑组合物及其应用 |
| CN112494532B (zh) * | 2020-12-17 | 2022-05-31 | 弘美制药（中国）有限公司 | 一种防掉发、滋养头皮的组合物及其制备方法与应用 |
| CN113662873B (zh) * | 2021-08-11 | 2023-08-22 | 广州杰铿生物科技有限公司 | 一种渗透组合物、护肤品及其制备方法 |
| CN114983856B (zh) * | 2022-08-03 | 2022-11-01 | 深圳市萱嘉生物科技有限公司 | 一种具有促渗体系的蓝铜肽溶液及其制备方法与应用 |
| CN121311214A (zh) * | 2023-06-09 | 2026-01-09 | 联合利华知识产权控股有限公司 | 辛酰基甘氨酸用于防止或减少毛发脱落的方法 |
| CN116549373B (zh) * | 2023-06-12 | 2025-12-02 | 武汉二十四桥生物科技有限公司 | 一种平衡皮肤油脂分泌的组合物及其制备方法和应用 |
| CN120617077B (zh) * | 2025-08-12 | 2025-11-11 | 广州源大生物科技有限公司 | 一种控油组合物、用途及护肤品 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009053163A1 (en) * | 2007-10-25 | 2009-04-30 | Unilever Plc | Hair care composition |
| EP2695611B1 (en) * | 2012-08-06 | 2014-10-01 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof |
| KR101550179B1 (ko) * | 2015-05-13 | 2015-09-03 | 주식회사 제이코스메틱스 | 탈모방지 및 모발성장 조성물 |
| CN109431912B (zh) * | 2018-12-27 | 2019-12-31 | 湖南御家化妆品制造有限公司 | 皮肤油脂平衡组合物及其应用 |
-
2019
- 2019-12-31 CN CN201911413315.8A patent/CN111110600B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111110600A (zh) | 2020-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111110600B (zh) | 一种头皮净化促生发组合物及其乳液 | |
| CN115607510B (zh) | 一种高浓度齐墩果酸纳米乳组合物及制备方法 | |
| CN103705421A (zh) | 一种牛奶补水抗衰老霜及其制造方法 | |
| CN119157768B (zh) | 适用于痘敏肌的祛痘防复发组合物及其应用 | |
| KR101762796B1 (ko) | 복합생약추출물의 발효물을 포함하는 탈모방지용 조성물 | |
| CN109010216A (zh) | 一种美白祛斑化妆品及其制备方法 | |
| JP2001206835A (ja) | コラーゲン合成促進剤及びコラーゲン代謝賦活剤 | |
| JP2008105983A (ja) | 線維芽細胞増殖促進剤、皮膚外用剤、浴用剤及び飲食物 | |
| JP2006241059A (ja) | ニキビ用皮膚化粧料 | |
| JPS6261924A (ja) | 皮膚外用剤 | |
| JPH07242526A (ja) | 化粧料 | |
| JP2640597B2 (ja) | 創傷治癒促進剤 | |
| KR20180020534A (ko) | 가바를 함유하는 효모추출물을 유효성분으로 포함하는 발모촉진 또는 탈모예방용 조성물 | |
| CN114788796B (zh) | 一种含福鼎白茶提取物的美白抗菌化妆品及其制备方法 | |
| CN113995701B (zh) | 一种祛痘和消除痘印的组合物及其制备方法和应用 | |
| KR20090059445A (ko) | 한약 추출물을 함유하는 양이온/음이온 계면활성제 혼합베시클을 함유하는 탈모 방지용 또는 모발 성장용 조성물 | |
| JP2008088075A (ja) | プロフィラグリン／フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮／角層正常化用皮膚外用剤、プロフィラグリン及び／又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法 | |
| JP3382148B2 (ja) | 頭部用外用剤 | |
| CN113768803A (zh) | 一种防脱发去屑喷剂的组合物及制备方法 | |
| CN106420483A (zh) | 一种净透黑头溶出液 | |
| CN118415901B (zh) | 具有水油同调功效的组合物及其制备方法和应用 | |
| CN111544564B (zh) | 一种婴儿尿布性皮炎药膏及其制备方法 | |
| WO1995006459A1 (en) | Stable composition containing wheat sprout juice and process for producing it | |
| JP5155543B2 (ja) | エンドセリン−１産生抑制剤、ヘキソサミニダーゼ遊離抑制剤、抗炎症用／美白用皮膚外用剤、エンドセリン−１の産生抑制方法及びヘキソサミニダーゼの遊離抑制方法 | |
| JPH11228355A (ja) | 頭部用外用剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518000 13 / f-13170, main tower, shipping center, 59 Linhai Avenue, Qianhai Shenzhen Hong Kong cooperation zone, Shenzhen City, Guangdong Province Applicant after: Quanhou (Shenzhen) Information Technology Co., Ltd Address before: 518000 13 / f-13170, main tower, shipping center, 59 Linhai Avenue, Qianhai Shenzhen Hong Kong cooperation zone, Shenzhen City, Guangdong Province Applicant before: QUANHOO (SHENZHEN) INVESTMENT DEVELOPMENT Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |